Skip to main content
. 2022 Apr 5;4(1):e000267. doi: 10.1136/bmjno-2022-000267

Table 3.

Outcomes at 3 months by PAS and antiplatelet therapy

Outcomes at 3 months Total Events, n (%) Unadjusted Adjusted
N=2818 OR (95% CI) P value OR (95% CI) P value
Recurrence of ischaemic stroke PAS+DAPT 393 44 (11.2) Reference Reference
PAS+SAPT 267 19 (7.12) 0.627 (0.366 to 1.073) 0.0887 0.605 (0.352 to 1.039) 0.0687
Non-PAS+DAPT 1229 51 (4.15) 0.361 (0.241 to 0.541) <0.0001 0.392 (0.260 to 0.590) <0.0001
Non-PAS+SAPT 929 36 (3.88) 0.338 (0.218 to 0.526) <0.0001 0.363 (0.232 to 0.567) <0.0001
Composite vascular events PAS+DAPT 393 47 (11.96) Reference Reference
PAS+SAPT 267 19 (7.12) 0.586 (0.344 to 0.998) 0.0493 0.563 (0.330 to 0.963) 0.0358
Non-PAS+DAPT 1229 54 (4.39) 0.358 (0.242 to 0.529) <0.0001 0.389 (0.262 to 0.579) <0.0001
Non-PAS+SAPT 929 37 (3.98) 0.325 (0.211 to 0.500) <0.0001 0.347 (0.225 to 0.537) <0.0001
Haemorrhagic stroke PAS+DAPT 393 1 (0.25) Reference Reference
PAS+SAPT 267 0 0 0.9980 0 0.9982
Non-PAS+DAPT 1229 2 (0.16) 0.638 (0.058 to 7.036) 0.7136 0.753 (0.066 to 8.658) 0.8200
Non-PAS+SAPT 929 0 0 0.9963 0 0.9962
mRS 3–6
(missing 25)*
PAS+DAPT 388 60 (15.46) Reference Reference
PAS+SAPT 263 33 (12.55) 0.784 (0.497 to 1.239) 0.2975 0.561 (0.337 to 0.937) 0.0270
Non-PAS+DAPT 1220 106 (8.69) 0.520 (0.370 to 0.731) 0.0002 0.672 (0.465 to 0.972) 0.0350
Non-PAS+SAPT 912 99 (10.86) 0.666 (0.471 to 0.940) 0.0209 0.731 (0.501 to 1.066) 0.1034

Adjustment for baseline characteristics includes age, sex, history of hypertension, history of diabetes and smoking.

*(mRS) Adjustment for baseline characteristics includes age, sex, history of hypertension, history of diabetes, smoking and NIHSS.

CI, confidence interval; DAPT, dual antiplatelet therapy; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratios; PAS, parent artery stenosis; SAPT, single antiplatelet therapy.